Report of Foreign Issuer (6-k)
27 Julho 2015 - 8:01AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 under
the
Securities Exchange Act of 1934
For the month ended
July 2015
ICON plc
(Registrant's
name)
333-08704
(Commission file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland
(Address of
principal executive offices)
Brendan Brennan, Chief Financial
Officer
South County Business Park, Leopardstown, Dublin 18, Ireland
Brendan.Brennan@iconplc.com
00-353-1-291-2000
(Name,
telephone number, email and/or facsmile number and address of Company
contact person)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Yes___X___ No_______
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___X___
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___X___
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes_______ No___X___
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b):82 N/A
EXHIBIT LIST
Exhibit
|
Description
|
|
|
99.1
|
ICON plc Press Release issued July 27, 2015 - ICON Shareholders
Vote in Favour of All Resolutions at its Annual General Meeting
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
ICON plc
|
|
|
|
|
|
|
|
|
|
|
|
|
Date:
|
July 27, 2015
|
/s/ Brendan Brennan
|
|
|
Brendan Brennan
|
|
|
Chief Financial Officer
|
Exhibit 99.1
ICON
Shareholders Vote in Favour of All Resolutions at its Annual General
Meeting
DUBLIN--(BUSINESS WIRE)--July 27, 2015--ICON plc (NASDAQ:
ICLR), a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries,
today announced that all resolutions at the Annual General Meeting of
the Company (AGM) held on July 24, 2015 (which resolutions had all been
recommended by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to shareholders
dated June 12, 2015 and are available on the ICON plc website.
The resolutions were all passed and the final results of proxy voting
were:
RESOLUTION NUMBER
|
|
|
|
RESOLUTION
|
|
|
|
TOTAL NUMBER OF VOTES
|
|
|
|
VOTE FOR
|
|
|
|
VOTE AGAINST
|
|
|
|
VOTE WITHHELD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.1
|
|
|
|
To re-elect Mr. Ciaran
Murray
|
|
|
|
50,029,986
|
|
|
|
49,567,723
|
|
|
|
247,632
|
|
|
|
214,631
|
1.2
|
|
|
|
To re-elect Dr. Ronan
Lambe
|
|
|
|
50,029,986
|
|
|
|
47,186,311
|
|
|
|
2,628,744
|
|
|
|
214,931
|
1.3
|
|
|
|
To re-elect Mr. Declan
McKeon
|
|
|
|
50,029,986
|
|
|
|
48,645,702
|
|
|
|
1,169,472
|
|
|
|
214,812
|
2
|
|
|
|
To receive accounts
and reports
|
|
|
|
50,029,986
|
|
|
|
49,641,405
|
|
|
|
3,516
|
|
|
|
385,065
|
3
|
|
|
|
To authorise the
fixing of the auditors’
remuneration
|
|
|
|
50,029,986
|
|
|
|
45,084,310
|
|
|
|
4,796,085
|
|
|
|
149,591
|
4**
|
|
|
|
To authorise the
Company to allot
shares
|
|
|
|
50,029,986
|
|
|
|
48,491,411
|
|
|
|
1,379,197
|
|
|
|
159,378
|
5**
|
|
|
|
To disapply
pre-emption rights
|
|
|
|
50,029,986
|
|
|
|
49,701,576
|
|
|
|
154,711
|
|
|
|
173,699
|
6**
|
|
|
|
To authorise the
Company to make
market purchases of
shares
|
|
|
|
50,029,986
|
|
|
|
49,004,400
|
|
|
|
149,069
|
|
|
|
876,517
|
7**
|
|
|
|
To authorise the price
range at which the
Company can
reissue shares it
holds as treasury
shares
|
|
|
|
50,029,986
|
|
|
|
49,842,211
|
|
|
|
27,891
|
|
|
|
159,884
|
|
** Special Resolution. All resolutions are ordinary resolutions unless
otherwise stated.
This press release contains forward-looking statements. These statements
are based on management's current expectations and information currently
available, including current economic and industry conditions. These
statements are not guarantees of future performance or actual results,
and actual results, developments and business decisions may differ from
those stated in this press release. The forward-looking statements are
subject to future events, risks, uncertainties and other factors that
could cause actual results to differ materially from those projected in
the statements, including, but not limited to, the ability to enter into
new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business
mergers and acquisitions, as well as economic and global market
conditions and other risks and uncertainties detailed from time to time
in SEC reports filed by ICON, all of which are difficult to predict and
some of which are beyond our control. For these reasons, you should not
place undue reliance on these forward-looking statements when making
investment decisions. The word "expected" and variations of such words
and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 81 locations in 37 countries and
has approximately 11,300 employees. Further information is available at www.iconplc.com.
ICON/ICLR-F
CONTACT:
All at ICON
Investor Relations, 1-888-381-7923
or
Brendan
Brennan, + 353 –1-291-2000
Chief Financial Officer
or
Simon
Holmes, + 353 –1-291-2000
EVP Investor Relations and Corporate
Development
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024